CervoMed neflamapimod nfvPPA biomarker data accepted at ISFTD 2026
CervoMed has announced that initial results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted as a late-breaking oral presentation at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia, running 8 to 11 October 2026.
The presentation, scheduled for the Plenary 6 "Hot Topics" session on 11 October, will cover 12-week data for two plasma biomarkers, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), from at least 22 of the 25 participants enrolled in the study. The abstract submitted for acceptance was based on the first eight participants, making the expanded dataset the headline number for the live session.
The drug and the disease
Neflamapimod is an orally administered, blood-brain-barrier-penetrant small molecule that selectively inhibits p38 MAP kinase alpha (p38α), an enzyme implicated in neuroinflammation and synaptic dysfunction. CervoMed positions the mechanism as broadly applicable to tau-driven neurodegeneration, which is the pathological substrate most commonly associated with nfvPPA.
nfvPPA is a subtype of frontotemporal dementia characterised by progressive loss of expressive speech and, in advanced stages, mutism and impaired motor planning. CervoMed estimates that between 10,000 and 15,000 people are living with the condition in the United States and 15,000 to 20,000 in the European Union. No treatment has been approved for nfvPPA in either jurisdiction, leaving an entirely open field for any candidate that can demonstrate disease modification. The FDA granted neflamapimod Orphan Drug Designation for frontotemporal dementia in 2024, conferring seven years of post-approval marketing exclusivity alongside fee exemptions and development support.
Regulatory and competitive context
The broader FTD field has historically suffered from a sparse clinical pipeline relative to Alzheimer's disease, though the approval of lecanemab and donanemab in Alzheimer's has sharpened investor and regulatory attention on adjacent tauopathies. NfL and GFAP have both attracted increasing interest as pharmacodynamic biomarkers in neurodegenerative studies, partly because the FDA has been willing to engage on their utility in accelerated approval pathways. How the ISFTD data are interpreted will depend heavily on the direction and magnitude of change in these markers relative to baseline, information CervoMed has not pre-released.
Neflamapimod's development portfolio extends beyond nfvPPA. CervoMed completed a Phase 2b trial in dementia with Lewy bodies (DLB) and announced in November 2025 that it had reached alignment with the FDA on a potential registration pathway in that indication. The company is currently seeking a strategic partner to fund a Phase 3 DLB programme, meaning its balance sheet position is a live consideration for investors assessing near-term risk. A first patient dosing in the EXPERTS-ALS Phase 2a trial is also expected before the end of 2026, widening the clinical footprint but also the capital demands.
The ISFTD presentation will be closely watched as an early signal on neflamapimod's mechanism in a tau-dominant population. Positive biomarker trends would strengthen the scientific rationale for the DLB partnering narrative as well as the nfvPPA programme, given the overlapping biology. Full clinical endpoints from the nfvPPA trial, including speech and language measures, are not expected to be part of this initial readout.